MANIFEST: Multiomic Platform for Cancer Immunotherapy.

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2025-05-02 DOI:10.1158/2159-8290.cd-25-0099

Kok Haw Jonathan Lim,Zayd Tippu,Pippa G Corrie,Michael Hubank,James Larkin,Trevor D Lawley,Mark Stares,Grant D Stewart,Amy Strange,Stefan N Symeonides,Bernadett Szabados,Nicholas C Turner,Tom Waddell,Santiago Zelenay,Manuel Salto-Tellez,Caroline Dive,Samra Turajlic,

引用次数: 0

Abstract

Immunotherapy has revolutionized survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-changing drug-induced toxicities, or rationalize treatment choices are still lacking. In response to this unmet clinical need, we introduce Multiomic ANalysis of Immunotherapy Features Evidencing Success and Toxicity, a tumor type-agnostic platform to provide deep profiling of patients receiving immunotherapy that will enable integrative identification of biomarkers and discovery of novel targets using artificial intelligence and machine learning.

查看原文本刊更多论文

MANIFEST：癌症免疫治疗的多组学平台。

免疫疗法已经彻底改变了许多癌症患者的生存结果。然而，能够可靠地区分治疗反应者和无反应者、预测潜在的危及生命和改变生命的药物引起的毒性或使治疗选择合理化的生物标志物仍然缺乏。为了满足这一未满足的临床需求，我们引入了免疫治疗特征的多组学分析，证明了成功和毒性，这是一个肿瘤类型不可知的平台，可以提供接受免疫治疗的患者的深度分析，这将使生物标志物的综合鉴定和使用人工智能和机器学习发现新的靶点成为可能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.